Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26909777 | 0.87 | VHL (0.69) | VHLOPRM1 | |
| SCHEMBL26909787 | 0.87 | VHL (0.69) | VHLOPRM1 | |
| SCHEMBL30570893 | 0.87 | VHL (0.69) | VHLOPRM1 | |
| SCHEMBL9640948 | 0.78 | POLB (0.60) | POLB | |
| SCHEMBL9609029 | 0.78 | POLB (0.60) | POLB | |
| SCHEMBL7042009 | 0.78 | POLB (0.60) | POLB | |
| SCHEMBL10746321 | 0.78 | POLB (0.60) | POLB | |
| SCHEMBL9640550 | 0.77 | POLB (0.69) | VHLPOLBCTRB1 | |
| SCHEMBL7173956 | 0.77 | POLB (0.69) | VHLPOLBCTRB1 | |
| SCHEMBL10739643 | 0.77 | POLB (0.69) | VHLPOLBCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | GENENTECH, INC. (US) | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | VHL, HIF1AN, EGLN2 | VHL 1/4885POLB 1446/4885OPRM1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.